NBI-74330 is a high-affinity CXCR3 antagonist that inhibits the binding of CXCR3 to its ligands CXCL10 and CXCL11, reduces the formation of atherosclerotic plaques in LDL receptor-deficient mice, and decreases the migration of CD4+ T cells and macrophages to the peritoneum.